These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 38690814

  • 1. Can FDG-PET assess the response to chemotherapy and predict tissue necrosis in osteosarcoma and Ewing sarcoma?
    Andreani L, Ipponi E, Ruinato AD, Lupi T, Di Sacco F, Volterrani D, Coccoli L, Capanna R.
    Folia Med (Plovdiv); 2024 Apr 30; 66(2):196-202. PubMed ID: 38690814
    [Abstract] [Full Text] [Related]

  • 2. 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
    Gaston LL, Di Bella C, Slavin J, Hicks RJ, Choong PF.
    Skeletal Radiol; 2011 Aug 30; 40(8):1007-15. PubMed ID: 21298431
    [Abstract] [Full Text] [Related]

  • 3. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
    Aryal A, Kumar VS, Shamim SA, Gamanagatti S, Khan SA.
    Clin Orthop Relat Res; 2021 Aug 01; 479(8):1768-1779. PubMed ID: 33635285
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis.
    Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O.
    Clin Nucl Med; 2000 Nov 01; 25(11):874-81. PubMed ID: 11079583
    [Abstract] [Full Text] [Related]

  • 5. Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.
    Raciborska A, Bilska K, Drabko K, Michalak E, Chaber R, Pogorzała M, Połczyńska K, Sobol G, Wieczorek M, Muszyńska-Rosłan K, Rychlowska-Pruszyńska M, Rodriguez-Galindo C, Dziuk M.
    Clin Transl Oncol; 2016 Feb 01; 18(2):189-95. PubMed ID: 26250765
    [Abstract] [Full Text] [Related]

  • 6. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
    Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, Ruf J, Furth C, Stöver B, Hautzel H, Henze G, Amthauer H.
    J Clin Oncol; 2007 Dec 01; 25(34):5435-41. PubMed ID: 18048826
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Staging and follow-up of a Ewing sarcoma patient using 18F-FDG PET/CT.
    Garcia JR, Castañeda A, Morales La Madrid A, Bassa P, Soler M, Riera E.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018 Dec 01; 37(6):387-389. PubMed ID: 29107752
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
    Palmerini E, Colangeli M, Nanni C, Fanti S, Marchesi E, Paioli A, Picci P, Cambioli S, Donati D, Cevolani L, De Paolis M, Gambarotti M, Ferrari S.
    Eur J Nucl Med Mol Imaging; 2017 Feb 01; 44(2):215-223. PubMed ID: 27645694
    [Abstract] [Full Text] [Related]

  • 13. Clinical and Prognostic Role of 18F-FDG PET/CT in Pediatric Ewing Sarcoma.
    Albano D, Dondi F, Schumacher RF, D'Ippolito C, Porta F, Giubbini R, Bertagna F.
    J Pediatr Hematol Oncol; 2020 Mar 01; 42(2):e79-e86. PubMed ID: 31135716
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.
    Bailly C, Leforestier R, Campion L, Thebaud E, Moreau A, Kraeber-Bodere F, Carlier T, Bodet-Milin C.
    PLoS One; 2017 Mar 01; 12(8):e0183841. PubMed ID: 28841702
    [Abstract] [Full Text] [Related]

  • 15. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?
    Ulaner GA, Magnan H, Healey JH, Weber WA, Meyers PA.
    AJR Am J Roentgenol; 2014 Apr 01; 202(4):859-67. PubMed ID: 24660717
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours.
    Györke T, Zajic T, Lange A, Schäfer O, Moser E, Makó E, Brink I.
    Nucl Med Commun; 2006 Jan 01; 27(1):17-24. PubMed ID: 16340719
    [Abstract] [Full Text] [Related]

  • 18. Staging of newly diagnosed Ewing sarcoma: Results of bone marrow aspiration and biopsy versus (18)FDG-PET/CT imaging for bone marrow involvement.
    Guinot A, Tabone-Eglinger S, Isnardi V, Bahri H, Surdez D, Delattre O, Pierron G, Villemeur M, Lapouble E, Brahmi M, Bouhamama A, Corradini N, Marec-Bérard P.
    Eur J Cancer; 2023 Jan 01; 179():56-64. PubMed ID: 36502618
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Utility of 18FDG PET/CT Versus Bone Scan for Identification of Bone Metastases in a Pediatric Sarcoma Population and a Review of the Literature.
    Tal AL, Doshi H, Parkar F, Abraham T, Love C, Ye K, Yang R, Hoang B, Loeb D, Chou A, Geller D, Moadel R.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):52-58. PubMed ID: 32815877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.